The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA)

American Heart Journal

Volumn 164, Issue 6, 2012, Pages 878-883

  Gullestad, Lars ^a,b   Ueland, Thor ^a,b   Kjekshus, John ^a   Nymo, Ståle H ^a,b   Hulthe, Johannes ^c,d   Muntendam, Pieter ^e   McMurray, John J V ^f   Wikstrand, John ^c   Aukrust, Pål ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF GOTHENBURG   (Sweden)

^d ASTRAZENECA R AND D   (Sweden)

^e BG Medicine Inc   (United States)

^f UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; GALECTIN 3; PLACEBO; ROSUVASTATIN;

AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; FEMALE; HEART DEATH; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; MAJOR CLINICAL STUDY; MALE; MORTALITY; PREDICTIVE VALUE; PRIORITY JOURNAL; SUDDEN DEATH; SYSTOLIC HEART FAILURE;

AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; FLUOROBENZENES; GALECTIN 3; HEART FAILURE, SYSTOLIC; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PROGNOSIS; PYRIMIDINES; STROKE; SULFONAMIDES;

EID: 84870300941     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.08.021     Document Type: Article

References (12)

1. D.L. Mann, and J.B. Young Basic mechanisms in congestive heart failure. Recognizing the role of proinnflammatory cytokines Chest 105 1994 897 904
2. U.C. Sharma, S. Pokharel, and T.J. van Brakel Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction Circulation 110 2004 3121 3128
3. N.C. Henderson, A.C. Mackinnon, and S.L. Farnworth Galectin-3 expression and secretion links macrophages to the promotion of renal fibrosis Am J Pathol 172 2008 288 298
4. R.R. van Kimmenade, J.L. Januzzi Jr., and P.T. Ellinor Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure J Am Coll Cardiol 48 2006 1217 1224
5. D.J.A. Lok, P. Van Der Mer, and P.W.-A. de la Porta Prognostic value of galectin-3, a novel marker of fibrosis, in patients with chronic heart failure: data from the DEAL-HF study Clin Res Cardiol 99 2010 323 328
6. R.A. de Boer, D.J. Lok, and T. Jaarsma Predictive value of plasma galectin-3 levels in heart failure with reduced and preserved ejection fraction Ann Med 43 2011 60 68
7. L. Gullestad, T. Ueland, and J. Kjekshus Galectin-3 predicts response to statin therapy in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA) Eur Heart J 2012 2290 2296
8. J. Kjekshus, E. Apetrei, and V. Barrios CORONA Group. Rosuvastatin in older patients with systolic heart failure [see comment] N Engl J Med 357 2007 2248 2261
9. J.G. Cleland, J.J. McMurray, and J. Kjekshus CORONA Study Group. Plasma concentration of amino-terminal pro-brain natriuretic peptide in chronic heart failure: prediction of cardiovascular events and interaction with the effects of rosuvastatin: a report from CORONA (Controlled Rosuvastatin Multinational Trial in Heart Failure) J Am Coll Cardiol 54 2009 1850 1859
10. J.J. McMurray, J. Kjekshus, and L. Gullestad CORONA Study Group. Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis Circulation 120 2009 2188 2196
11. H. Wedel, J.J. McMurray, and M. Lindberg Predictors of fatal and non-fatal outcomes in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): incremental value of apolipoprotein A-1, high-sensitive C-reactive peptide and N-terminal pro B-type natriuretic peptide Eur J Heart Fail 11 2009 281 291
12. M.J. Pencina, R.B. D'Agostino Sr., and E.W. Steyerberg Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers Stat Med 30 2011 11 21